Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity
- PMID: 18213512
- DOI: 10.1007/s10930-007-9118-8
Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity
Abstract
Type A botulinum neurotoxin is one of the most lethal of the seven serotypes and is increasingly used as a therapeutic agent in neuromuscular dysfunctions. Its toxic function is related to zinc-endopeptidase activity of the N-terminal light chain (LC) on synaptosome-associated protein-25 kDa (SNAP-25) of the SNARE complex. To understand the determinants of substrate specificity and assist the development of strategies for effective inhibitors, we used site-directed mutagenesis to investigate the effects of 13 polar residues of the LC on substrate binding and catalysis. Selection of the residues for mutation was based on a computational analysis of the three-dimensional structure of the LC modeled with a 17-residue substrate fragment of SNAP-25. Steady-state kinetic parameters for proteolysis of the substrate fragment were determined for a set of 16 single mutants. Of the mutated residues non-conserved among the serotypes, replacement of Arg-230 and Asp-369 by polar or apolar residues resulted in drastic lowering of the catalytic rate constant (k(ca)), but had less effect on substrate affinity (K(m)). Substitution of Arg-230 with Lys decreased the catalytic efficiency (k(cat)/K(m)) by 50-fold, whereas replacement by Leu yielded an inactive protein. Removal of the electrostatic charge at Asp-369 by mutation to Asn resulted in 140-fold decrease in k(cat)/K(m). Replacement of other variable residues surrounding the catalytic cleft (Glu-54, Glu-63, Asn-66, Asp-130, Asn-161, Glu-163, Glu-170, Glu-256), had only marginal effect on decreasing the catalytic efficiency, but unexpectedly the substitution of Lys-165 with Leu resulted in fourfold increase in k(cat)/K(m). For comparison purposes, two conserved residues Arg-362 and Tyr-365 were investigated with substitutions of Leu and Phe, respectively, and their catalytic efficiency decreased 140- and 10-fold, respectively, whereas substitution of the tyrosine ring with Asn abolished activity. The altered catalytic efficiencies of the mutants were not due to any significant changes in secondary or tertiary structures, or in zinc content and thermal stability. We suggest that, despite the large minimal substrate size for catalysis, only a few non-conserved residues surrounding the active site are important to render the LC competent for catalysis or provide conformational selection of the substrate.
Similar articles
-
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.PLoS One. 2010 Sep 22;5(9):e12872. doi: 10.1371/journal.pone.0012872. PLoS One. 2010. PMID: 20877571 Free PMC article.
-
Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization.Biochemistry. 2002 Feb 12;41(6):1717-23. doi: 10.1021/bi0157969. Biochemistry. 2002. PMID: 11827515
-
Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain.Biochemistry. 2000 Mar 7;39(9):2399-405. doi: 10.1021/bi992321x. Biochemistry. 2000. PMID: 10694409
-
Structure and biological activity of botulinum neurotoxin.J Physiol (Paris). 1990;84(3):220-8. J Physiol (Paris). 1990. PMID: 2074545 Review.
-
Structure, Oligomerization and Activity Modulation in N-Ribohydrolases.Int J Mol Sci. 2022 Feb 25;23(5):2576. doi: 10.3390/ijms23052576. Int J Mol Sci. 2022. PMID: 35269719 Free PMC article. Review.
Cited by
-
Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin.PLoS One. 2014 Apr 25;9(4):e95188. doi: 10.1371/journal.pone.0095188. eCollection 2014. PLoS One. 2014. PMID: 24769566 Free PMC article.
-
Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.J Comput Aided Mol Des. 2014 Jul;28(7):765-78. doi: 10.1007/s10822-014-9758-7. Epub 2014 Jun 24. J Comput Aided Mol Des. 2014. PMID: 24958623 Free PMC article.
-
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.Toxins (Basel). 2012 Oct;4(10):913-39. doi: 10.3390/toxins4100913. Epub 2012 Oct 19. Toxins (Basel). 2012. PMID: 23162705 Free PMC article. Review.
-
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.PLoS One. 2010 Sep 22;5(9):e12872. doi: 10.1371/journal.pone.0012872. PLoS One. 2010. PMID: 20877571 Free PMC article.
-
Tyrosine phosphorylation of botulinum neurotoxin protease domains.Front Pharmacol. 2012 Jun 4;3:102. doi: 10.3389/fphar.2012.00102. eCollection 2012. Front Pharmacol. 2012. PMID: 22675300 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous